Shire has signed an agreement to acquire FerroKin BioSciences, Inc. for an upfront payment of $100 million in cash, plus potential milestone payments totaling $225 million based on development, regulatory and sales targets. The acquisition expands Shire’s hematology business with Phase II drug FBS0701, a once-daily oral capsule in development for the treatment of iron overload due to chronic blood transfusions in adults and children. FBS0701 has received Orphan Product designation from bot...